23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
July 2017 in “OPAL (Open@LaTrobe) (La Trobe University)” High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
1 citations
,
January 2024 in “Nature communications” Activating TLR5 in the gut can extend lifespan and improve health in aged mice.
February 2026 in “Advanced Science” TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.
October 2024 in “Journal of the Endocrine Society” Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.
Not having the gene PLAAT3 leads to fat loss, high insulin resistance, and abnormal fat levels in the blood due to a disruption in fat cell development and function.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
31 citations
,
October 2010 in “Progress in lipid research” LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
55 citations
,
June 2014 in “Nature Communications” Tcf3 helps cells move and heal wounds by controlling lipocalin 2.
13 citations
,
December 2009 in “Journal of the Peripheral Nervous System” TRPA1 and TRPV1 channels don't affect mechanotransduction in rat sinus hair follicles.
53 citations
,
April 2016 in “Stem cell research & therapy” LL-37 helps stem cells grow and move, aiding tissue regeneration and hair growth.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
September 2023 in “Journal of the American Academy of Dermatology”
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
69 citations
,
October 2013 in “Journal of Clinical Psychopharmacology” Naltrexone did not significantly reduce hair pulling but improved cognitive flexibility.
26 citations
,
August 2018 in “Journal of Investigative Dermatology” Activating TRPV3 reduces skin oil production and increases inflammation, potentially causing dry skin issues.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
March 2026 in “American Journal of Clinical Dermatology” 33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
3 citations
,
May 2025 in “Cell Death and Disease” Targeting METTL1 may help slow papillary thyroid cancer growth and spread.
14 citations
,
August 2015 in “Endocrinology” The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.